JP2022512703A5 - - Google Patents

Info

Publication number
JP2022512703A5
JP2022512703A5 JP2021520915A JP2021520915A JP2022512703A5 JP 2022512703 A5 JP2022512703 A5 JP 2022512703A5 JP 2021520915 A JP2021520915 A JP 2021520915A JP 2021520915 A JP2021520915 A JP 2021520915A JP 2022512703 A5 JP2022512703 A5 JP 2022512703A5
Authority
JP
Japan
Prior art keywords
sequence
seq
guide
nos
guide rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021520915A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512703A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/056399 external-priority patent/WO2020081613A1/en
Publication of JP2022512703A publication Critical patent/JP2022512703A/ja
Publication of JP2022512703A5 publication Critical patent/JP2022512703A5/ja
Priority to JP2025093281A priority Critical patent/JP2025138662A/ja
Pending legal-status Critical Current

Links

JP2021520915A 2018-10-16 2019-10-15 免疫療法のための組成物および方法 Pending JP2022512703A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025093281A JP2025138662A (ja) 2018-10-16 2025-06-04 免疫療法のための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862746522P 2018-10-16 2018-10-16
US62/746,522 2018-10-16
US201862747037P 2018-10-17 2018-10-17
US62/747,037 2018-10-17
PCT/US2019/056399 WO2020081613A1 (en) 2018-10-16 2019-10-15 Compositions and methods for immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025093281A Division JP2025138662A (ja) 2018-10-16 2025-06-04 免疫療法のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2022512703A JP2022512703A (ja) 2022-02-07
JP2022512703A5 true JP2022512703A5 (cg-RX-API-DMAC7.html) 2022-10-24

Family

ID=68502008

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021520915A Pending JP2022512703A (ja) 2018-10-16 2019-10-15 免疫療法のための組成物および方法
JP2025093281A Pending JP2025138662A (ja) 2018-10-16 2025-06-04 免疫療法のための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025093281A Pending JP2025138662A (ja) 2018-10-16 2025-06-04 免疫療法のための組成物および方法

Country Status (15)

Country Link
US (2) US12630820B2 (cg-RX-API-DMAC7.html)
EP (1) EP3867379A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022512703A (cg-RX-API-DMAC7.html)
KR (1) KR20210091160A (cg-RX-API-DMAC7.html)
CN (1) CN113227374A (cg-RX-API-DMAC7.html)
AU (2) AU2019362879C1 (cg-RX-API-DMAC7.html)
BR (1) BR112021007025A2 (cg-RX-API-DMAC7.html)
CA (1) CA3116132A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021006301A2 (cg-RX-API-DMAC7.html)
IL (1) IL282225B1 (cg-RX-API-DMAC7.html)
MX (1) MX2021004214A (cg-RX-API-DMAC7.html)
PH (1) PH12021550849A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202103571XA (cg-RX-API-DMAC7.html)
TW (1) TW202035693A (cg-RX-API-DMAC7.html)
WO (1) WO2020081613A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
CN116096892A (zh) * 2020-05-08 2023-05-09 宏基因组学公司 具有RuvC结构域的酶
WO2022093846A1 (en) * 2020-10-26 2022-05-05 Arsenal Biosciences, Inc. Safe harbor loci
AU2021368740A1 (en) * 2020-10-30 2023-06-01 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting trac and uses thereof
MX2023006878A (es) 2020-12-11 2023-07-31 Intellia Therapeutics Inc Composiciones y métodos para reducir el mhc de clase ii en una célula.
EP4267723A1 (en) 2020-12-23 2023-11-01 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying ciita in a cell
WO2022140586A2 (en) 2020-12-23 2022-06-30 Intellia Therapeutics, Inc. Compositions and methods for reducing hla-a in a cell
JP2024502036A (ja) 2020-12-30 2024-01-17 インテリア セラピューティクス,インコーポレイテッド 操作されたt細胞
WO2022170193A2 (en) 2021-02-08 2022-08-11 Intellia Therapeutics, Inc. T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy
EP4288088A2 (en) 2021-02-08 2023-12-13 Intellia Therapeutics, Inc. Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy
JP2024505672A (ja) 2021-02-08 2024-02-07 インテリア セラピューティクス,インコーポレイテッド 免疫療法のためのナチュラルキラー細胞受容体2b4組成物及び方法
CN117083292A (zh) * 2021-04-02 2023-11-17 科济生物医药(上海)有限公司 Cs1工程化细胞及其组合物
JP2024534114A (ja) 2021-08-24 2024-09-18 インテリア セラピューティクス,インコーポレイテッド 細胞療法用のプログラム細胞死タンパク質1(pd1)組成物及び方法
CN119452085A (zh) 2021-08-27 2025-02-14 宏基因组学公司 具有ruvc结构域的酶
WO2023081200A2 (en) 2021-11-03 2023-05-11 Intellia Therapeutics, Inc. Cd38 compositions and methods for immunotherapy
KR20240110603A (ko) 2021-11-24 2024-07-15 메타지노미, 인크. 엔도뉴클레아제 시스템
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
US20250268940A1 (en) 2022-04-19 2025-08-28 Intellia Therapeutics, Inc. Chimeric antigen receptor compositions and uses
WO2023225670A2 (en) * 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
EP4540389A2 (en) 2022-06-16 2025-04-23 Intellia Therapeutics, Inc. Compositions and methods for reducing mhc class i in a cell
WO2024006955A1 (en) 2022-06-29 2024-01-04 Intellia Therapeutics, Inc. Engineered t cells
EP4608979A1 (en) * 2022-10-28 2025-09-03 CorrectSequence Therapeutics (Shanghai) Co., Ltd Gene editing systems and methods for reducing immunogenicity and graft versus host response
TW202503051A (zh) 2023-03-07 2025-01-16 美商英特利亞醫療公司 用於免疫療法之cish組合物及方法
WO2025038646A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Cd70 car-t compositions and methods for cell-based therapy
TW202515994A (zh) 2023-08-14 2025-04-16 美商英特利亞醫療公司 用於對cd70進行基因修飾之組合物及方法
WO2025038648A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
WO2025038637A1 (en) 2023-08-14 2025-02-20 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
WO2025049631A1 (en) * 2023-08-28 2025-03-06 Kyverna Therapeutics, Inc. Allogeneic car-t cell therapies and manufacture thereof
WO2025077790A1 (en) * 2023-10-11 2025-04-17 Chengdu Ucello Biotechnology Co., Limited Engineered immune cells and uses thereof
WO2025128871A2 (en) 2023-12-13 2025-06-19 Renagade Therapeutics Management Inc. Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
IL330230A (en) 2023-12-20 2026-08-01 Intellia Therapeutics Inc Engineered T cells
WO2025255308A1 (en) 2024-06-07 2025-12-11 Intellia Therapeutics, Inc. Cd8 co-receptor chimeric polypeptides in tcr cell therapy

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
ATE515510T1 (de) 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc Durch dna-abschnitte unterbrochene modifizierte oligonukleotide
EP0760008A1 (en) 1994-05-19 1997-03-05 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
PT2931898E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições para manipulação de sequências com domínios funcionais
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
AU2014235968B2 (en) * 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
US20150166984A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting alpha-antitrypsin point mutations
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
RU2752933C2 (ru) 2014-03-11 2021-08-11 Селлектис Способ создания т-клеток, пригодных для аллогенной трансплантации
SG11201608701QA (en) * 2014-04-18 2016-11-29 Editas Medicine Inc Crispr-cas-related methods, compositions and components for cancer immunotherapy
WO2015200555A2 (en) 2014-06-25 2015-12-30 Caribou Biosciences, Inc. Rna modification to engineer cas9 activity
EP3177314B1 (en) 2014-08-04 2020-10-07 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
KR102546296B1 (ko) * 2014-10-31 2023-06-21 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도
US9848522B2 (en) 2014-11-07 2017-12-26 Dawn Equipment Company Agricultural system
US9723778B2 (en) 2014-11-07 2017-08-08 Dawn Equipment Company Agricultural system
AU2016226077B2 (en) 2015-03-03 2021-12-23 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases with altered PAM specificity
EP4019635A1 (en) * 2015-03-25 2022-06-29 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
BR112017020750A2 (en) * 2015-03-27 2018-06-26 President And Fellows Of Harvard College modified t-cells and methods of producing and using them
EP3277294B1 (en) * 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
ES2803728T3 (es) 2015-10-05 2021-01-29 Prec Biosciences Inc Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
WO2017070429A1 (en) 2015-10-22 2017-04-27 Regents Of The University Of Minnesota Methods involving editing polynucleotides that encode t cell receptor
WO2017093969A1 (en) * 2015-12-04 2017-06-08 Novartis Ag Compositions and methods for immunooncology
US11352631B2 (en) * 2015-12-18 2022-06-07 Sangamo Therapeutics, Inc. Targeted disruption of the T cell receptor
WO2017112944A1 (en) * 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
MX2018010484A (es) * 2016-03-04 2019-01-10 Editas Medicine Inc Métodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cáncer.
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
KR102614675B1 (ko) 2016-04-15 2023-12-19 메모리얼 슬로안 케터링 캔서 센터 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법
EP3452499A2 (en) 2016-05-06 2019-03-13 Juno Therapeutics, Inc. Genetically engineered cells and methods of making the same
CN106191062B (zh) * 2016-07-18 2019-06-14 广东华南疫苗股份有限公司 一种tcr-/pd-1-双阴性t细胞及其构建方法
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
EP3551757A1 (en) 2016-12-08 2019-10-16 Intellia Therapeutics, Inc. Modified guide rnas
US20200087681A1 (en) 2016-12-21 2020-03-19 Ucl Business Plc Therapeutic cells
AU2018208614A1 (en) * 2017-01-10 2019-07-11 The General Hospital Corporation Modified T cells and methods of their use
US10934336B2 (en) * 2017-04-13 2021-03-02 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
EA201992536A1 (ru) 2017-04-24 2020-03-05 Оспедале Сан Раффаэле С.Р.Л. Tcr и пептиды
BR112019023608A2 (pt) * 2017-05-12 2020-05-26 Crispr Therapeutics Ag Materiais e métodos para células manipuladas e seus usos em imuno-oncologia
EP3686275A4 (en) 2017-09-18 2021-09-29 Edigene Inc. GENE EDITING LYMPHOCYTE T AND RELATED USE
EP3688162B1 (en) 2017-09-29 2024-03-06 Intellia Therapeutics, Inc. Formulations
US11952408B2 (en) 2017-10-03 2024-04-09 Juno Therapeutics, Inc. HPV-specific binding molecules
CN107723275B (zh) * 2017-10-20 2020-09-04 重庆精准生物技术有限公司 通用型car-t细胞及其制备方法和应用
EP3703712A4 (en) * 2017-10-30 2021-09-22 PACT Pharma, Inc. EDITING PRIMARY CELL GENES
CN109750035B (zh) * 2017-11-02 2020-06-05 上海邦耀生物科技有限公司 靶向并引导Cas9蛋白高效切割TCR及B2M基因座的sgRNA
CN107828730B (zh) * 2017-11-07 2019-04-30 南京北恒生物科技有限公司 具有抗体药物抗性的通用型cart/tcrt细胞及其构建方法
CN107746831B (zh) * 2017-11-07 2019-04-23 南京北恒生物科技有限公司 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法
CN112585276A (zh) * 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
CN112585277A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 表达重组受体的t细胞、相关多核苷酸和方法
WO2019210281A1 (en) * 2018-04-27 2019-10-31 Casebia Therapeutics Limited Liability Partnership Methods and compositions of cytotoxic t cell depletion
WO2019210280A1 (en) * 2018-04-27 2019-10-31 Casebia Therapeutics Limited Liability Partnership Anti-bcma car-t-cells for plasma cell depletion

Similar Documents

Publication Publication Date Title
JP7490704B2 (ja) 遺伝子組換えにより内在性foxp3遺伝子の発現が安定化されたcd4 t細胞を使用した自己免疫疾患の治療方法
US20200299661A1 (en) Cpf1-related methods and compositions for gene editing
EP3368689B1 (en) Composition for modulating immune responses by use of immune cell gene signature
US11186825B2 (en) Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1
US11180730B2 (en) Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3
US20190262399A1 (en) Compositions and methods for evaluating and modulating immune responses
KR20230053591A (ko) 조작된 근육 표적화 조성물
TW202425951A (zh) 脂質奈米顆粒藥物綴合物
CN114144423B (zh) 使用与免疫检查点抑制剂组合递送的siRNA沉默TGF-BETA 1和COX2以治疗癌症
US20230000912A1 (en) Genetic, developmental and micro-environmental programs in idh-mutant gliomas, compositions of matter and methods of use thereof
TW202425952A (zh) 脂質奈米顆粒藥物綴合物
JP2022519070A (ja) 免疫療法の改善のための遺伝子調節組成物及び遺伝子調節方法
JP2023085547A (ja) snoRNAの発現抑制剤を有効成分とするがん増殖抑制剤
CN116096886A (zh) 用于调节叉头框p3(foxp3)基因表达的组合物和方法
CN117716026A (zh) 具有氧化应激抗性的间充质干细胞、其制备方法及用途
WO2024152937A1 (zh) 靶向fgf2的基因编辑系统及其应用
KR20200129959A (ko) 무-운반체 다중 CRISPR/Cas 9 유전자 편집 복합체 및 그의 용도
WO2025147949A1 (zh) 基因编辑系统及其应用
US20220290157A1 (en) Compositions and methods for treating amyotrophic lateral sclerosis
CN114072518B (zh) 用于治疗地中海贫血或镰状细胞病的方法和组合物
US20090060889A1 (en) Ii-RNAi involved Ii suppression in cancer immunotherapy
EP4640830A1 (en) Means and methods for safe and efficient gene editing in cells
US20250375465A1 (en) Methods for affecting tissue-resident t cells
TW202535429A (zh) 包含5'utr-3'utr組合的多核苷酸及其用途
WO2025088508A1 (en) Means and methods for genetic modification of uba1